How NIH contributions to drug discovery get obscured; Gilead foresees more growth in HIV drugs

Taking stock of the drug industry, from the lab to the medicine chest

May 5, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | NIH grant recipients often fail to disclose agency support in patent applications Lack of patent information may obscure the crucial role the NIH plays in discovering or developing new medicines. By Ed Silverman STAT+ | Gilead foresees more growth in its HIV drugs Gilead's CEO believes the foundation of the company will continue to be its HIV franchise, particularly PrEP. By Bob Herman Opinion: Clinical trials for Alzheimer's treatments need to include people with Down syndrome Around 70% of people with Down syndrome will be diagnosed with Alzheimer's in their 40s and 50s. Bringing them into clinical trials is a must. By Michelle Sie Whitten Sarah Gonzalez for STAT STAT+ | Doudna talks cost, access issues looming over first CRISPR therapy The CRISPR pioneer urges colleagues to think about technologies can bring down the cost of manufacturing these therapies. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser